[Clinical observation of aripiprazole in the treatment of autism]

ArticleinZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 15(4):294-7 · April 2013with4 Reads
DOI: 10.7499/j.issn.1008-8830.2013.04.012 · Source: PubMed


    To study the effect and safety of aripiprazole in the treatment of childhood autism.
    Thirty-five children (aged from 4 to 16 years) with autism presenting as behavioral disorders were treated with aripiprazole for 8 weeks. They were evaluated according to the Clinical Global Impression (CGI) and the Autism Treatment Evaluation Checklist (ATEC) before treatment and at the end of the 2nd, 4th and 8th weeks of treatment. Adverse reactions were observed.
    The CGI showed illness severity decreased from the second week of aripiprazole treatment (P<0.05) and more significantly decreased illness severity was observed at the end of the 8th week (P<0.01). The curative effect score significantly increased at the end of the 8th week (P<0.05). The ATEC total scores were significantly reduced at the end of the 8th week after aripiprazole treatment. Besides the social intercourse ability, great improvements were shown in verbal communication, apperception and behavioural symptoms after aripiprazole treatment (P<0.01). Self-harm, sleep disorders and psychiatric symptoms were greatly improved after treatment and attention deficit, excessive activities, impulse to attack behavior, stereotyped behaviors and irritability were also improved to some extent. No severe adverse effects were found.
    Aripiprazole is safe and effective for the treatment of childhood autism.